Medicine and Dentistry
Odds Ratio
100%
Cross Sectional Study
100%
Observational Study
100%
Multiple Myeloma
100%
Lenalidomide
50%
Blood Transfusion
40%
Surgical Infection
40%
Urinary Tract Infection
40%
Acute Kidney Injury
40%
Bortezomib
37%
Progression Free Survival
37%
Overall Survival
37%
M Protein
25%
Adverse Event
25%
Postoperative Complication
20%
Chi Square Test
20%
Surgical Mortality
20%
Bone Lesion
12%
Biochemical Recurrence
12%
Neutropenia
12%
Carfilzomib
12%
Immunoglobulin A
12%
Treatment Withdrawal
12%
Time to Treatment
12%
Proteasome Inhibitor
12%
Daratumumab
12%
Population Research
12%
Retrospective Study
12%
Cancer Therapy
12%
Cancer Research
12%
Kaplan Meier Method
12%
Biological Marker
12%
Symptomatic Treatment
12%
Immunoglobulin
12%
Anemia
12%
Survival Time
12%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Observational Study
100%
Lenalidomide
50%
Progression Free Survival
37%
Bortezomib
37%
Overall Survival
37%
M Protein
25%
Adverse Event
25%
Malignant Neoplasm
25%
Immunoglobulin
12%
Immunoglobulin A
12%
Bone Lesion
12%
Anemia
12%
Carfilzomib
12%
Daratumumab
12%
Neutropenia
12%
Proteasome Inhibitor
12%
Survival Time
12%
Biochemical Recurrence
12%
Biological Marker
12%
Retrospective Study
12%
Population Study
12%
Immunology and Microbiology
Multiple Myeloma
100%
Lenalidomide
50%
Progression Free Survival
37%
Overall Survival
37%
Population Research
12%
Proteasome
12%
Immunoglobulin Blood Level
12%
Daratumumab
12%
Survival Time
12%
Immunoglobulin A
12%